Kitea Health
Overview
Executive Summary
Kitea Health is revolutionising hydrocephalus management with the Kitea System, a wireless, implantable brain pressure monitoring device. Our technology, backed by over 20 years of research and $15 million in grants, aims to reduce unnecessary hospital visits and improve patient outcomes. With a total addressable market of $2 billion in the US alone, Kitea Health is seeking $10 million in investment to fund pivotal trials and secure FDA approval.
Problem and Solution
Hydrocephalus is a life-threatening condition affecting over a million people in the US, with 50% of shunts failing within the first 2 years. Shunts are recognised to have the highest failure rate of any medical device. Kitea Health's solution, the Kitea System, offers real-time, remote monitoring of intracranial pressure, enabling early intervention and reducing false alarms.
Highlights & Milestones
- Fully developed technology with proven biocompatibility and performance in animals.
- Strong IP portfolio with filed patents, including wireless power and data communication technologies.
- First human clinical trial commenced in NZ in June 2024. Adult enrolment complete, children now underway. US trial approval expected in late 2025.
- Total addressable market of $2 billion for hydrocephalus, with potential for expansion into cardiac monitoring markets.
Market Opportunity
Hydrocephalus affects an estimated 6.4 million people globally, with 1 million in the US alone. The Kitea System addresses a significant market need, with potential to reduce healthcare costs and improve patient outcomes.
Competitive Advantage
- Unique technology as the world's smallest brain implant, offering remote monitoring and minimal surgical impact.
- Wireless, long-term monitoring with high accuracy and MRI compatibility.
- Cost savings through reduced ED visits and improved patient outcomes.
Exit Strategy
Kitea Health aims to file for FDA approval in 2027, positioning the company for acquisition by larger medical device companies. This strategic exit will leverage our technology for global impact.
Use of Funds
- Complete First-In-Human Trials in in children in NZ.
- Secure FDA Investigational Device Exemption (IDE) for US trials.
- Scale device manufacturing to meet growing demand.
We invite you to explore our full deal room for more detailed information and to join us in transforming hydrocephalus management
Highlights & Milestones
Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.
Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.
Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.
Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non orci maximus mollis. Cras commodo venenatis lectus vel fringilla.
Proin mollis, magna consequat placerat tempus, lectus dui porttitor augue, eget vulputate orci augue nec nisl. Integer sagittis vitae nibh vitae finibus. Vestibul
Open an account to get
access to more details
Problem and Solution
Cras eleifend purus vitae mattis imperdiet.
Integer fringilla mi ut sem tincidunt, in sagittis odio mollis. Suspendisse a diam lectus. Cras at suscipit risus.
Fusce gravida, ante quis mattis ultricies, lorem neque suscipit ex, semper tincidunt dui mi sit amet elit.
Fusce scelerisque massa sit amet turpis rutrum semper.
Donec ac orci aliquet, tincidunt ligula eu, finibus libero. Pellentesque pharetra consequat congue. Pellentesque quis dolor augue.
Proin non ipsum vel risus rutrum porta. Vivamus sem enim, interdum pretium metus eu, ornare posuere nisl. Duis venenatis accumsan enim, quis blandit lacus posuere at. Sed tincidunt congue blandit. Maecenas interdum quam in mauris condimentum luctus. Donec fermentum egestas risus vel cursus. Ut metus justo, rutrum vel sem ut, consequat laoreet ante. Nunc tincidunt viverra metus, tincidunt viverra elit iaculis sit amet. Integer ullamcorper hendrerit eleifend. Curabitur massa nisi, tempus eget fermentum quis, volutpat non sem. Integer id sagittis dolor. Donec nunc erat, maximus sed magna id, faucibus ultricies velit. Nunc lobortis eget urna at semper.
Donec sollicitudin, tortor ac interdum tempus, mi odio fringilla lacus, sit amet hendrerit mi purus vel nisi. Phasellus nulla ligula, congue quis ullamcorper eget, egestas id leo. Sed et rhoncus libero. Mauris tincidunt ultricies justo ut tincidunt. Nam rhoncus est non erat auctor mattis. Sed quis consectetur ma
Open an account to get
access to more details
Exit Strategy
Ut dignissim eget felis non ultrices. Vivamus fermentum erat at velit varius molestie.
Duis vitae mi neque.
Donec tincidunt, dolor luctus lobortis ultrices, turpis eros cursus turpis, maximus tempor lectus lectus vel diam.
Proin neque lacus, semper vel ex at, eleifend rhoncus est.
Cras non nisi urna. Sed feugiat dignissim erat, eget convallis nisl blandit a. Nullam fringilla diam eget dui placerat fermentum. Maecenas malesuada viverra leo eu bibendum. Nam vulputate enim velit, eu pretium justo tristique ac.
Nam vitae varius augue. Nam pharetra facilisis elementum. Sed nisl risus, vestibulum ut velit at, dapibus sagittis arcu. Nullam sed dolor suscipit, efficitur enim quis, vestibulum sapien. Nunc convallis mauris nec nibh mo
Open an account to get
access to more details
Market Opportunity
Pellentesque tempor a risus in elementum. Proin malesuada mauris et mauris bibendum laoreet.
Vivamus maximus nulla volutpat, ornare lorem a, vulputate enim. In dui nisl, vestibulum eu finibus pretium, eleifend et eros. Vivamus in venenatis risus, ut dictum velit. Praesent rhoncus tempor fermentum. In malesuada tellus eu volutpat posuere. Nullam ut dignissim libero, ut pharetra leo. Nullam sit amet aliquam felis. Suspendisse volutpat ante eget tincidunt feugiat. Nunc placerat sapien et metus molestie, in viverra augue viverra. Donec varius metus ut arcu vestibulum hendrerit. Sed viverra risus neque, ac commodo enim lacinia at.
Morbi posuere tortor vitae sapien faucibus auctor. Donec nulla ipsum, aliquet non bibendum sit amet, viverra non metus. Sed blandit efficitur orci, id dignissim eros.
Donec sollicitudin massa ut tellus gravida, ut luctus lacus maximus. Maecenas porttitor a tellus ac sagittis. Suspendisse potenti. Donec mauris sem, tristique a ipsum vitae, pretium facilisis libero. Nullam interdum mauris in euismod pretium. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Nunc felis lectus, ornare a nunc eu, convallis suscipit elit. Donec at magna non orci maximus mollis. Cras commodo venenatis lectus vel fringilla.
Proin mollis, magna consequat placerat tempus, lectus dui porttitor augue, eget vulputate orci augue nec nisl. Integer sagittis vitae nibh vitae finibus. Vestibul
Open an account to get
access to more details
See more exiting opportunities on CapitalHQ
Pictor
Powering diagnostics with protein signatures. Pictor is transforming health with its patented platform providing accessible, affordable, and scalable diagnostic solutions across the human and animal health verticals. PictArray can detect up to 10 diseases or biomarkers from one small serum, milk,...
ProxyTwin
ProxyTwin™ amplifies expertise. ProxyTwin is a digital twin that works for experts so they can help more people. We create advanced digital replicas of real individuals, enabling them to virtually attend meetings, deliver messages, and hold thousands of interactions simultaneously. Recently...
HorizonTwo Capital Partners
HorizonTwo Capital Partners is a private equity firm that specialises in advanced manufacturing companies.
The Insides Company
First-in-class medtech for intestinal failure. Seeking remaining $1M of a $5M round, on a AUD$17.2M pre-money valuation.
DCARB
We are aiming to raise $CAD5M to fund the ongoing commercialisation of the D100 unit, including working capital to fund the expected growth in sales, and a field trial of the DArc unit. This follows a successful Series B round completed in mid-2023.
Grabba Technologies Pty Ltd
Advanced manufacturer of biometric identity authorisation products and electronics supplier to defence industry. We invite expressions of interest for up to $10.0M in growth capital.
Backed By Leading Investment Groups and Family Offices
